The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts

Paola Secchiero, Carlotta Zerbinati, Elisabetta Melloni, Daniela Milani, Diana Campioni, Roberto Fadda, Mario Tiribelli, Giorgio Zauli

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis in primary acute myeloid leukemia (AML) blasts and promoted myeloid maturation of surviving cells, as demonstrated by analysis of CD11b and CD14 surface antigens and by morphologic examination. Although the best-characterized activity of Nutlin-3 is activation of the p53 pathway, Nutlin-3 induced maturation also in one AML sample characterized by p53 deletion, as well as in the p53-/- human myeloblastic HL-60 cell line. At the molecular level, the maturational activity of Nutlin-3 in HL-60 cells was accompanied by the induction of E2F1 transcription factor, and it was significantly counteracted by specific gene knockdown with small interfering RNA for E2F1. Moreover, Nutlin-3, as well as tumor necrosis factor (TNF) α, potentiated the maturational activity of recombinant TNF-related apoptosis-inducing ligand (TRAIL) in HL-60 cells. However, although TNF-α significantly counteracted the proapoptotic activity of TRAIL, Nutlin-3 did not interfere with the proapoptotic activity of TRAIL. Taken together, these data disclose a novel, potentially relevant therapeutic role for Nutlin-3 in the treatment of both p53 wild-type and p53-/- AML, possibly in association with recombinant TRAIL.

Original languageEnglish
Pages (from-to)853-861
Number of pages9
JournalNeoplasia (United States)
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2007

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
HL-60 Cells
Acute Myeloid Leukemia
Tumor Necrosis Factor-alpha
E2F1 Transcription Factor
CD14 Antigens
Apoptosis
Gene Knockdown Techniques
Surface Antigens
nutlin 3
Small Interfering RNA
Ligands
Cell Line
Therapeutics

Keywords

  • Acute myeloid leukemia
  • Apoptosis
  • HL-60 cells
  • p53 pathway
  • Surface antigens

ASJC Scopus subject areas

  • Cancer Research

Cite this

Secchiero, P., Zerbinati, C., Melloni, E., Milani, D., Campioni, D., Fadda, R., ... Zauli, G. (2007). The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia (United States), 9(10), 853-861. https://doi.org/10.1593/neo.07523

The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. / Secchiero, Paola; Zerbinati, Carlotta; Melloni, Elisabetta; Milani, Daniela; Campioni, Diana; Fadda, Roberto; Tiribelli, Mario; Zauli, Giorgio.

In: Neoplasia (United States), Vol. 9, No. 10, 10.2007, p. 853-861.

Research output: Contribution to journalArticle

Secchiero, P, Zerbinati, C, Melloni, E, Milani, D, Campioni, D, Fadda, R, Tiribelli, M & Zauli, G 2007, 'The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts', Neoplasia (United States), vol. 9, no. 10, pp. 853-861. https://doi.org/10.1593/neo.07523
Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia (United States). 2007 Oct;9(10):853-861. https://doi.org/10.1593/neo.07523
Secchiero, Paola ; Zerbinati, Carlotta ; Melloni, Elisabetta ; Milani, Daniela ; Campioni, Diana ; Fadda, Roberto ; Tiribelli, Mario ; Zauli, Giorgio. / The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. In: Neoplasia (United States). 2007 ; Vol. 9, No. 10. pp. 853-861.
@article{95c0651ee48b46ee942c0ccaadfc85a4,
title = "The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts",
abstract = "The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis in primary acute myeloid leukemia (AML) blasts and promoted myeloid maturation of surviving cells, as demonstrated by analysis of CD11b and CD14 surface antigens and by morphologic examination. Although the best-characterized activity of Nutlin-3 is activation of the p53 pathway, Nutlin-3 induced maturation also in one AML sample characterized by p53 deletion, as well as in the p53-/- human myeloblastic HL-60 cell line. At the molecular level, the maturational activity of Nutlin-3 in HL-60 cells was accompanied by the induction of E2F1 transcription factor, and it was significantly counteracted by specific gene knockdown with small interfering RNA for E2F1. Moreover, Nutlin-3, as well as tumor necrosis factor (TNF) α, potentiated the maturational activity of recombinant TNF-related apoptosis-inducing ligand (TRAIL) in HL-60 cells. However, although TNF-α significantly counteracted the proapoptotic activity of TRAIL, Nutlin-3 did not interfere with the proapoptotic activity of TRAIL. Taken together, these data disclose a novel, potentially relevant therapeutic role for Nutlin-3 in the treatment of both p53 wild-type and p53-/- AML, possibly in association with recombinant TRAIL.",
keywords = "Acute myeloid leukemia, Apoptosis, HL-60 cells, p53 pathway, Surface antigens",
author = "Paola Secchiero and Carlotta Zerbinati and Elisabetta Melloni and Daniela Milani and Diana Campioni and Roberto Fadda and Mario Tiribelli and Giorgio Zauli",
year = "2007",
month = "10",
doi = "10.1593/neo.07523",
language = "English",
volume = "9",
pages = "853--861",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts

AU - Secchiero, Paola

AU - Zerbinati, Carlotta

AU - Melloni, Elisabetta

AU - Milani, Daniela

AU - Campioni, Diana

AU - Fadda, Roberto

AU - Tiribelli, Mario

AU - Zauli, Giorgio

PY - 2007/10

Y1 - 2007/10

N2 - The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis in primary acute myeloid leukemia (AML) blasts and promoted myeloid maturation of surviving cells, as demonstrated by analysis of CD11b and CD14 surface antigens and by morphologic examination. Although the best-characterized activity of Nutlin-3 is activation of the p53 pathway, Nutlin-3 induced maturation also in one AML sample characterized by p53 deletion, as well as in the p53-/- human myeloblastic HL-60 cell line. At the molecular level, the maturational activity of Nutlin-3 in HL-60 cells was accompanied by the induction of E2F1 transcription factor, and it was significantly counteracted by specific gene knockdown with small interfering RNA for E2F1. Moreover, Nutlin-3, as well as tumor necrosis factor (TNF) α, potentiated the maturational activity of recombinant TNF-related apoptosis-inducing ligand (TRAIL) in HL-60 cells. However, although TNF-α significantly counteracted the proapoptotic activity of TRAIL, Nutlin-3 did not interfere with the proapoptotic activity of TRAIL. Taken together, these data disclose a novel, potentially relevant therapeutic role for Nutlin-3 in the treatment of both p53 wild-type and p53-/- AML, possibly in association with recombinant TRAIL.

AB - The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis in primary acute myeloid leukemia (AML) blasts and promoted myeloid maturation of surviving cells, as demonstrated by analysis of CD11b and CD14 surface antigens and by morphologic examination. Although the best-characterized activity of Nutlin-3 is activation of the p53 pathway, Nutlin-3 induced maturation also in one AML sample characterized by p53 deletion, as well as in the p53-/- human myeloblastic HL-60 cell line. At the molecular level, the maturational activity of Nutlin-3 in HL-60 cells was accompanied by the induction of E2F1 transcription factor, and it was significantly counteracted by specific gene knockdown with small interfering RNA for E2F1. Moreover, Nutlin-3, as well as tumor necrosis factor (TNF) α, potentiated the maturational activity of recombinant TNF-related apoptosis-inducing ligand (TRAIL) in HL-60 cells. However, although TNF-α significantly counteracted the proapoptotic activity of TRAIL, Nutlin-3 did not interfere with the proapoptotic activity of TRAIL. Taken together, these data disclose a novel, potentially relevant therapeutic role for Nutlin-3 in the treatment of both p53 wild-type and p53-/- AML, possibly in association with recombinant TRAIL.

KW - Acute myeloid leukemia

KW - Apoptosis

KW - HL-60 cells

KW - p53 pathway

KW - Surface antigens

UR - http://www.scopus.com/inward/record.url?scp=35448932303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448932303&partnerID=8YFLogxK

U2 - 10.1593/neo.07523

DO - 10.1593/neo.07523

M3 - Article

VL - 9

SP - 853

EP - 861

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 10

ER -